A 2025 review in the Journal of Clinical Medicine pulls together the clinical case for kisspeptin — the hypothalamic peptide that switches on reproductive hormones — across IVF triggering, hypothalamic amenorrhea, PCOS and male-factor infertility. Kisspeptin-based IVF triggering is the closest to the clinic, cutting the risk of severe ovarian hyperstimulation syndrome dramatically versus the standard hCG trigger, though short half-life and tachyphylaxis still limit dosing.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.